BioNexus Gene Lab Corp (OTC: BGLC) is a Malaysia-based healthcare company that operates two business segments: blood-based genomic screening services through its MRNA Scientific subsidiary and specialty chemicals distribution through its Chemrex subsidiary. MRNA Scientific generates revenue by analyzing RNA expression patterns from blood samples and delivering disease-risk reports to referring healthcare providers, covering conditions including selected cancers, inflammatory conditions, and osteoarthritis. Chemrex sells specialty chemical products through direct marketing, a warehouse showroom, and an online channel at chemrex.com.my. Total consolidated revenue was $7.4M for the year ended December 31, 2025, down from $9.5M for the year ended December 31, 2024. Related-party revenue accounted for $68,104 of the FY2025 total. The company is headquartered in Kuala Lumpur, Malaysia, with laboratory facilities in Kuala Lumpur and Penang. As of late 2025, BGLC entered a licensing agreement with Fidelion Diagnostics Pte Ltd for exclusive Southeast Asia rights to the VitaGuard MRD platform, with a committed license fee of $2.0M paid over 24 monthly installments.

Revenue model

Transactional revenue from two segments: genomic screening service fees billed per test through MRNA Scientific, and product sales of specialty chemicals through Chemrex. Chemrex top 5 customers represented 27.43% of FY2025 revenue, with the largest single customer at 8.09% ($599,018). No subscription or recurring-contract structure is disclosed for either segment.

Products and services

MRNA Scientific: blood-based RNA expression screening assays covering 11 disease categories including nasopharyngeal cancer, colon cancer subtypes, osteoarthritis, and inflammatory conditions; personalized risk-score reports delivered to referring healthcare providers; VitaGuard Minimal Residual Disease (MRD) platform licensed from Fidelion Diagnostics for the Southeast Asia market. Chemrex: specialty chemicals distributed through a wholesale distribution center, website (chemrex.com.my), and direct sales personnel.

Customers and end markets

MRNA Scientific serves healthcare providers (physicians and clinics) who order genomic screening on behalf of patients. Chemrex serves business customers in Malaysia; its top 5 customers in FY2025 were unnamed but collectively contributed 27.43% of Chemrex revenue. End markets include clinical diagnostics, cancer screening, and industrial or commercial chemicals.

Value-chain role

BGLC sits at the laboratory-services layer for genomic screening: it receives blood samples, performs RNA extraction and microarray analysis using proprietary software, and delivers risk-score reports to healthcare providers. For chemicals, it acts as a wholesale distributor, purchasing from suppliers and reselling to end customers. The company does not manufacture reagents or chemical inputs.

Geographic exposure

Operations are concentrated in Malaysia, with offices and laboratories in Kuala Lumpur and Penang. The VitaGuard license covers the Southeast Asia market. A shareholder entity is based in Singapore (Fidelion Diagnostics Pte Ltd) and another in Shanghai (ARC Group International Limited), but no revenue breakdown by geography outside Malaysia is disclosed in the filing.

Source: SEC 10-K, filed 2026-04-14

Industry: Services-Medical Laboratories